FLUOR DE LYS®-HDAC8 deacetylase substrateBML-KI178-0005
荧光组蛋白去乙酰化酶8 二乙酰化多肽底物
纯度95%
保存-80度
状态5 mM溶液 (100 ul )
货号
产品名称
规格
中文名称
品牌
BML-KI178-0005
FLUOR DE LYS® – HDAC8 deacetylase substrate
0.5 umol
荧光组蛋白去乙酰化酶8 二乙酰化多肽底物
ENZO(美国)
文献引用
Compromised Structure and Function of HDAC8 Mutants Identified in Cornelia de Lange Syndrome Spectrum Disorders: C. Decroos, et al.; ACS Chem. Biol. 9, 2157 (2014), Application(s): Assay of human HDAC8, Abstract;
Molecular Basis for the Antiparasitic Activity of a Mercaptoacetamide Derivative That Inhibits Histone Deacetylase 8 (HDAC8) from the Human Pathogen Schistosoma mansoni: D. Stolfa, et al.; J. Mol. Biol. 426, 3442 (2014), Application(s): In vitro HDAC inhibition assay of parasitic flatworm, Abstract;
Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni: M. Marek, et al.; PLoS Pathog. 9, e1003645 (2013), Application(s): Human and smHDAC8 activity assay, Abstract;Full Text
Insights from comprehensive multiple receptor docking to HDAC8: M. Brunsteiner, et al.; J. Mol. Model. 18, 3927 (2012),Abstract;
Sterile Acrodisc® Syringe Filters with Supor® Membrane 产品英文简介： ● Superior flow rates and higher throughputs than competitive devices ● Low protein binding to minimize sample loss ● Sterilized by gamma irradiation to eliminate potential contamination by EtO residuals ● A range of sizes （13 to 37 mm） accommodates sample volumes from < 10 to 150 mL ● Acrodisc PF and serum Acrodisc syringe filters feature built-in difficult-to-filter liquids ● Reduces mycoplasma with the use of 0.1µm pore size
Applications: ● 0.1 and 0.2µm pore sizes provide sterilization of small volumes of buffers, culture media, and additives ● Acrodisc PF and Serum Acrodisc syringe filters are ideal for clarification/sterilization of viscous or particulate-laden solutions ● Use larger pore size filters for prefiltration and particulate removal
Diapharma Group INC成立于1997年，研究人员具有多年临床以及研发经验，专注于血液病领域的试剂盒，试剂以及仪器，主要涵盖血栓形成、止血、血小板功能分析、细胞凋亡、生态毒理学等。
Diapharma Group INC成立于1997年，研究人员具有多年临床以及研发经验，专注于血液病领域的试剂盒，试剂以及仪器，主要涵盖血栓形成、止血、血小板功能分析、细胞凋亡、生态毒理学等。
The Diapharma Group, Inc. formed on January 1, 1997 from Pharmacia Hepar, Inc. in Franklin, Ohio, and began as the exclusive US and Canadian distributor of the Chromogenix substrates and assays.
Over a quarter-century ago, Chromogenix developed the first chromogenic substrate technology under the former name, Kabi Diagnostica. Kabi later merged with Pharmacia. Some of Diapharma’s current staff worked inside the Chromogenix department within Pharmacia’s heparin manufacturing plant.
In 1998, Diapharma moved to West Chester, Ohio, where it remains today. Over the years, Diapharma expanded its product line to include a variety of hemostasis, cell death, plate-let function, ecotoxicology, assays, reagents, antibodies and instruments from superior manufacturers.
AdipoGen® Multimeric Proteins are high activity constructs in which two trimeric TNFSF ligands are linked via the oligomeric collagen domain of ACRP30 [ACRP30headless] and therefore mimic the membrane-bound forms of the proteins.
Endogenous TNF superfamily ligands are either active as membrane- form (e.g. FasL, TRAIL, CD40L, OX40L) or are secreted and activated through oligomerization by the binding of pro-teoglycans at the surface of cells (e.g. APRIL).
To mimic endogenous TNF ligands activity, the oligomerization of recombinant TNF ligands can be triggered:
• by fusing the TNF superfamily ligands, soluble form, to the collagen domain of the protein ACRP30 (which itself has no functional activity) to form a hexameric structure and therefore creating “Multimeric Proteins”, or
• by adding a cross-linking antibody called “TNF Ligands Enhancer” (Prod. No. AG-35B-0001).
MultimericFasL. [MegaFasL.]
FasL (human) (multimeric) (rec.)
AG-40B-0130 10 µg | 3 x 10 µg
MultimericFasL™ very effectively simulates the natural membrane-assisted aggregation of FasL in vivo.
Source: HEK 293 cells.
Sequence: Human FasL (aa 139-281) is fused at the
N-terminus to mouse ACRP30headless
(aa 18-111) and a FLAG®-tag.
Specificity: Binds to human and mouse Fas.
Biological Activity: Induces apoptosis of human Jurkat
T cells at a concentration of<1ng>
Endotoxin Content: <0.01EU/μg purified protein (LAL test; Lonza).
LITerature references: Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex: N. Holler, et al.; Mol. Cell. Biol. 23, 1428 (2003) • A Fas agonist induces high levels of apoptosis in haematological malignancies: P. Greaney, et al.; Leuk. Res. 30, 415 (2006)
Figure: Oligomerisation of FasL (human) efficiently triggers Jurkat cell death.
Method: Jurkat cells were treated O/N with the indicated concentrations of FasL (human)(multimeric) (rec.) (AG-40B-0130), Fc (human):FasL (human) (rec.) (AG-40B-0132), FasL (human) (rec.) (AG-40B-0001) or FasL (human) (rec.) + Enhancer (AG-44B- 0001) (2 fold-dilutions, first concentration of 1000ng/ml). Cell death was quantified using PMS/MTS. The oligomeric FasL recombinant proteins (FasL (human) (multimeric), Fc (human):FasL (human) and FasL (human) + Enhancer) kill Jurkat cells at IC50 <0.2ng/ml.
See Backcover for more Products!
• MultiPacks for additional big savings !
• Bulk Quantities for in vivo cancer immunotherapy and vaccination studies in mice !
MultimericCD40L™
CD40L (human) (multimeric) (rec.)
AG-40B-0010-C010 10 µg | 3 x 10 µg
• MultimericCD40L™ very effectively mimics the naturalmembrane-assisted aggregation of CD40L. It is the most potent alternative to activate CD40. No enhancer is required.
• MultimericCD40L™ is a potent B cell activator.
LITerature reference: IgG subclass switch capacity is low in switched and in IgM-
only, but high in IgD+IgM+, post-germinal center (CD27+) human B cells: C. Werner-Favre, et al.; Eur. J. Immunol. 31, 243 (2001)
CD 40L (mouse) (multimeric) (rec.) AG-40B-0020 10 μg | 3 x 10 μg
CD 40L (rat) (multimeric) (rec.) AG-40B-0107 10 μg | 3 x 10 μg
Bulk available for in vivo studies!
Full Panel of MultimericLigands™
APRIL (human) (multimeric) (rec.) AG-40B-0017 10 μg | 3 x 10 μg
APRIL (human) (H98) (multimeric) (rec.) AG-40B-0088 10 μg | 3 x 10 μg
Same activity as AG-40B-0017. Does not bind proteoglycans.
APRIL (mouse) (multimeric) (rec.) AG-40B-0089 10 μg | 3 x 10 μg
APRIL (mouse) (H98) (multimeric) (rec.) AG-40B-0035 10 μg | 3 x 10 μg Same activity as AG-40B-0089. Does not bind proteoglycans.
